Literature DB >> 12923437

Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis.

Hanni S Alho1, Paula K Maasilta, Ari L J Harjula, Pekka Hämmäinen, Jukka Salminen, Ulla-Stina Salminen.   

Abstract

BACKGROUND: In posttransplant obliterative bronchiolitis (OB), the major pathologic features are inflammation, epithelial cell injury, fibrosis, and obliteration of the small airways. Tumor necrosis factor (TNF)-alpha is a cytokine known to mediate and augment the inflammatory reaction and to enhance fibroblast proliferation. We assessed the role of TNF-alpha in the development of OB in our heterotopic porcine bronchial transplantation model.
METHODS: Three groups were formed: autografts, nontreated allografts, and allografts treated with preoperative anti-TNF-alpha monoclonal antibody (infliximab) infusion. The implants were harvested on days 2, 4, 7, 11, 14, 21, and 28 for histologic and immunohistochemical analysis.
RESULTS: TNF-alpha inhibition reduced inflammation, rate of epithelial loss, fibrosis, and obliteration early in the development of OB. In the epithelium, the numbers of TNF-alpha-positive epithelial and inflammatory cells and macrophages were significantly lower in treated than in nontreated allografts on day 4; furthermore, in the epithelium and in the bronchial wall, invasion of CD8+ lymphocytes was significantly decreased during the first week.
CONCLUSIONS: These results indicate that TNF-alpha promotes the development of OB, and inhibition of TNF-alpha may prove beneficial in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923437     DOI: 10.1097/01.TP.0000074700.30536.76

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

Authors:  Kyu-Hyoung Lim; Ho-Il Yoon; Young Ae Kang; Keun-Wook Lee; Jee Hyun Kim; Soo-Mee Bang; Jae Ho Lee; Choon-Taek Lee; Jong Seok Lee
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 3.165

Review 2.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

Review 3.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

4.  Rituximab-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Ahmet B Ergin; Nancy Fong; Hamed A Daw
Journal:  Case Rep Med       Date:  2012-06-19

5.  Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis.

Authors:  Valeria Sainz-Prestel; Jesus Hernandez-Perez; Jorge Rojas-Rivera; José María Milicua-Muñoz; Jesus Egido; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2013-09-01

Review 6.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

Review 7.  Cytokine mediated tissue fibrosis.

Authors:  Lee A Borthwick; Thomas A Wynn; Andrew J Fisher
Journal:  Biochim Biophys Acta       Date:  2012-10-06

8.  Local C-reactive protein expression in obliterative lesions and the bronchial wall in posttransplant obliterative bronchiolitis.

Authors:  Outi E Päiväniemi; Paula K Maasilta; Tiina L S Vainikka; Hanni S Alho; Pekka J Karhunen; Ulla-Stina Salminen
Journal:  Mediators Inflamm       Date:  2009-05-26       Impact factor: 4.711

9.  Rituximab-induced interstitial lung disease: five case reports.

Authors:  Matiuallah Naqibullah; Saher B Shaker; Karen S Bach; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2015-05-21

10.  Tumor necrosis factor-α blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study.

Authors:  Christelle Nguyen; Clémence Palazzo; Sophie Grabar; Antoine Feydy; Katherine Sanchez; Nathalie Zee; Laurent Quinquis; Myriam Ben Boutieb; Michel Revel; Marie-Martine Lefèvre-Colau; Serge Poiraudeau; François Rannou
Journal:  Arthritis Res Ther       Date:  2015-11-19       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.